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OBJECTIVES: Limited information exists on utility in CRPC patients, especially in
mCRPC patients who progress after first line therapy. This study is to describe
correlates of utility assessments in patients with mCRPC who have progressed
during or after docetaxel first-line therapy. METHODS: An observational study of
mCRPC patients progressing during or after the first-line docetaxel therapy was
performed in US, France, Germany and UK. Patient characteristics, first-line treat-
ment details and quality of life using a generic EQ-5D questionnaire were evaluated
at the time of second line treatment decision. Descriptive analyses and multivari-
ate analysis for EQ-5D utility index are presented. RESULTS: Eighty-two patients
were recruited in the study and 74 patients had an evaluable EQ-5D questionnaire.
In this subset the median age was 72 years and 81% had a good ECOG performance
status (ECOG-PS score 0 or 1). The mean ( SD) utility index was 0.63 ( 0.26).
Relationship between utility index and potential correlates was analysed using
univariate regressions. Age, ECOG-PS and time since diagnosis were related with
the utility score, but stage at diagnosis, time between last dose of treatment and
progression, total number of docetaxel cycles and response to first line treatment were
not. After multivariate adjustment for these correlates and accounting for country
variation, ECOG-PS (0-1 versus 2-3) was the strongest predictor of utility index
(p.0001), with a strong utility increment of 0.38 for ECOG-PS 0-1 patients. Age (18-64,
65-74, 3 75 years) and time since diagnosis (2, 2-4, 4-8,8 years) were not statistically
significant (p0.127 and 0.072, respectively). There was no difference between coun-
tries (p0.329). CONCLUSIONS: In metastatic prostate cancer patients who have
reached castration-resistant stage and progressed after first-line docetaxel,
ECOG-PS is the strongest correlate of utility score measured by EQ-5D. This finding
appears equally applicable across several European countries and US.
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OBJECTIVES: To develop a mapping algorithm for a conversion of the EORTC QLQ-
C30 and EORTC QLQ BR-23 into the EQ-5D derived utilities in metastatic breast
cancer (MBC) patients.METHODS:We enrolled 199 patients with MBC from the four
leading Korean hospitals in 2009. EQ-5D utility, cancer-specific (QLQ-C30) and
breast cancer-specific quality of life data (QLQ-BR23), and selected clinical and
demographic information were collected from the study participants. Ordinary
least squares regression models were used to model the EQ-5D using QLQ-C30 and
QLQ-BR23 scale scores. To select the best model specification, six different sets of
explanatory variables were compared. RESULTS: Regression analysis with the
multi-item scale scores of QLQ-C30 was the best-performing model, explaining for
48.7% of the observed EQ-5D variation. Its mean absolute error between the ob-
served and predicted EQ-5D utilities (0.092) and relative prediction error (2.784%)
was among the smallest. Also, this mapping model showed the least systematic
errors according to disease severity. CONCLUSIONS: The mapping algorithms de-
veloped have good predictive validity and therefore they enable researchers to
translate cancer-specific health-related quality-of-life measures to the preference-
adjusted health status of MBC patients.
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OBJECTIVES: Skeletal related events (SREs) are a major cause of morbidity for cas-
tration resistant prostate cancer (CRPC) patients with bone metastases. SREs can
have a debilitating effect on patient’s quality of life (QoL), although severity de-
pends on the type of SRE. The purpose of this study is to determine what data are
available on utility weights by SRE type for use in a cost-utility analysis of CRPC.
METHODS: A systematic literature review of PubMed was performed to identify
data on SRE utilities. The search was limited to the past 10 years and to metastatic
cancer and bone neoplasms. RESULTS: The search yielded 82 articles, of these 19
contained SRE and utility information only 8 of which reported utility weights. One
article reported a utility decrement for hip fractures (0.03) in CRPC. Another re-
ported utility decrements for pathologic fractures (0.13) and radiation to bone (0.07)
in metastatic prostate cancer (mPCa). Two articles contained utility data differen-
tiated per SRE for non-small-cell lung carcinoma (NSCLC) and advanced renal cell
carcinoma (aRCC). These decrements were calculated using a multiplier per SRE
derived from an earlier study in metastatic breast cancer (mBCa) and ranged from
0.05 for vertebral fractures to 0.50-0.61 for spinal cord compression. The other 4
articles only reported the overall utility, but did not specify per type of SRE.
CONCLUSIONS: To accurately model the impact of SREs on CRPC, QoL utility
weights should be assigned to each SRE type to account for their varying severity.
This study found only one article with a utility weight for a specific SRE in CRPC and
one for mPCa. However, the use of SRE utility weights derived from a mBCa study
for measuring SRE decrements in NSCLC and aRCC suggest SRE utility weights
derived from other cancers may be acceptable for a CRPC cost-utility analysis.
PCN131
SYSTEMATIC EVALUATION OF SPECIFIC QUALITY OF LIFE INSTRUMENTS FOR
PROSTATE CANCER
Schmidt S, Pardo Y, Vilagut G, Garin O, Pont A, Cunillera O, Becerra V, Ferrer M
IMIM (Institut de Recerca Hospital del Mar), Barcelona, Catalunya, Spain
OBJECTIVES: This study aims to perform a systematic expert evaluation of the
measurement properties of specific health-related quality of life instruments for
prostate cancer. METHODS: We conducted a systematic literature search to iden-
tify articles about specific health-related quality of life instruments developed for
prostate cancer. Secondly, titles and abstracts were reviewed independently by two
experts and, in case of discrepancies, by a third expert to filter the information.
Thirdly, for every instrument identified, two experts reviewed the articles about
measurement properties and applied the EMPRO tool (Evaluating the Measurement
of Patient-Reported Outcomes), which was specifically designed for a standardized
evaluation of measurement properties of PRO instruments regarding: conceptual
and measurement model, reliability, validity and responsiveness among other.
Scores are transformed to a scale from 0 to 100. RESULTS: Ten specific question-
naires were indentified with great variability regarding available information on
measurement properties (between 2 and 13 articles): DALE questionnaire (2), ES-
CAP_CDV (2), TALCOTT questionnaire (2), PCQoL (3), EORTC QLQ PR-25 (3), PORPUS
(3), PROSQOLI (4), EPIC (7), FACT-P (11) and UCLA-PCI (13). Only 5 out of 10 ques-
tionnaires provided full information regarding their measurement properties. Re-
garding their conceptual and measurement model, EPIC demonstrated the highest
score (90), followed by UCLA-PCI, PROSQOLI, Talcott questionnaire, PCQoL,
EORTC PR25, and PORPUS (50). Only three questionnaires presented high reliabil-
ity scores (EPIC and PCQoL 80, UCLA-PCI 50). UCLA-PCI showed the highest
scores for validity (80), followed by PORPUS and PCQoL (70), PROSQOLI and EPIC
(50). Highest responsiveness scores were observed for PCQoL (100), EPIC and POR-
PUS (80), and PROSQOLI (70).CONCLUSIONS: In this systematic evaluation, only
2 out of 10 questionnaires provided information supporting their conceptual and
measurement model, as well as good reliability, validity and responsiveness: EPIC
and PCQoL. All instruments have a psychometric design except PORPUS, which
was designed to perform cost-utility analysis.
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OBJECTIVES: : To develop QI (Quality Indicator) specialized for evaluating domicil-
iary palliative care and to explore the relationship of this QI with family satisfaction
as a typical outcome of palliative care service at home. METHODS: A modified
Delphi method was adopted to select potential QIs and rate the appropriateness
and feasibility of them by multi-professional specialists engaged at home palliative
care. A retrospective study on the medical records to examine relation between the
developed QIs and FAMCARE (score of family satisfaction) was conducted on 44
patients with cancer who received home palliative care service between 2001 and
2008 at a regional clinic in Japan. RESULTS: Twelve indicators were selected and
included some items concerning long-term care insurance, surroundings and re-
habilitation. A number compatible with the QIs was 7.5  3.4 and found to have
weak relationship with length of the home care (correlation coefficient 0. 298
(p0.05)). It also showed correlation with FAMCARE average scores (correlation
coefficient 0. 431 (p0.04)). CONCLUSIONS: These QIs seem to be useful for moni-
toring and evaluating home palliative care but have some problems such as mix-
ture of indicators for evaluating end-of-life care and care in the stable stage. The
number of QIs documented on the charts was related with the FAMCARE score,
which might be affected by the period of the home care.
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OBJECTIVES: Integrative therapy may focus on the synergic effect of complemen-
tary therapies to increase effectiveness of conventional treatment. Korean cancer
patients may expect better care with integrative cancer therapy of combining con-
ventional western treatment with traditional Korean medicine (TKM), and eventu-
ally determine their satisfaction with the outcomes of treatment. The objective of
this study was to investigate patients’ expectation and satisfaction with the inte-
grative cancer therapy.METHODS:A total of 102 cancer patients were participated.
Due to the specialty of Integrative Cancer Center (ICC) for those who received only
western treatment received care elsewhere. Based on clinical decision at ICC, pa-
tients received either integrative treatment with combining conventional treat-
ment with TKM (n55) or TKM only (n43). At ICC, Rhus verniciflua Stokes Extract
which is described in the literature was used as TKM. We use Korean translation of
Cancer Therapy Satisfaction Questionnaire (CTSQ) to measure patients’ expecta-
tion and satisfaction. RESULTS: Mean age was 51.9 and most were stage 4 (74.4%).
In the integrative therapy group, mean scores of Expectations of Therapy (ET),
Feelings about Side Effects (FSE), Satisfaction with Therapy (SWT) domains were
80.7/15.0, 74.9/23.5, and 73.7/14.6, respectively, whereas in the TKM
group, mean scores of ET, FSE, SWT were 80.8/16.8, 87.5/19.3, and 78.1/
14.5, respectively. Only FSE was statistically different between the two groups
(p.0054). Similar results were seen in stage 4 patients. Cronbach’s alpha of this
Korean CTSQ domains were acceptable (0.74-0.86). CONCLUSIONS: Previously
treated cancer patients in particular, eventually seek additional care with integra-
tive cancer therapy. Their expectation about integrative cancer therapy, however,
was not much different from traditional medicine. This may due to hard experi-
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ence from battling cancer such as side effects from conventional western cancer
treatment. The findings of this study suggest that cancer patients regardless of
stage may expect and satisfy with less toxic treatments with less side effects .
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OBJECTIVES: Treatment decisions for patients diagnosed with advanced non-
small cell lung cancer (NSCLC) require assessment of the risks and benefits of
treatment. We sought to understand the patient perspective when making these
choices by estimating utilities (preference weights and relative importance
weights) for different hypothetical NSCLC treatment profiles.METHODS:One hun-
dred patients with NSCLC were recruited in the UK and completed a self-adminis-
tered, web-based conjoint analysis questionnaire. The questionnaire presented
patients with pair-wise choices of NSCLC treatment profiles which systematically
varied the duration of progression-free survival (PFS), severity of disease symp-
toms, severity of the treatment-related adverse events (diarrhea, fatigue, fever/
infection, nausea/vomiting and rash) and mode of treatment administration (in-
travenous versus oral). Preference weights were estimated using a random-
parameters logit. Importance weights were calculated from the model coefficients.
RESULTS: Eighty-nine patients (73% male) completed all choice tasks appropri-
ately. The highest utility was associated with treatments that increased PFS and
improved disease-related symptom severity from severe to mild (10.0; 95% CI: 6.1,
13.9). However, patients preferred a reduction in PFS if disease-related symptoms
were severe. Utility was higher for treatments that had no fatigue (5.0; 95% CI: 2.7,
7.3), no diarrhea (2.8; 95% CI: 0.7, 4.9), no fever/infection (2.1; 95% CI: 0.2, 4.1), no
nausea/vomiting (2.1; 95% CI: 0.1, 4.1), no rash (2.0; 95% CI: 0.2, 3.9) and for oral
administration instead of infusion (1.8; 95% CI: 0.0, 3.6). Patients were found to be
indifferent to treatments associated with mild diarrhea and mild nausea/vomiting.
Avoiding moderate fatigue was half as important as increasing PFS by seven
months with improvement in symptom severity from severe to mild.
CONCLUSIONS:NSCLC patients attributed the highest utility to treatment efficacy.
Treatments that increased PFS with low severity of disease related symptoms, no
fatigue and oral administration were preferred.
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OBJECTIVES: Oral chemotherapy generates for hospitals additional resources for
therapeutic education and health care coordination currently not taken into ac-
count in reimbursement tariffs. This may influence the prescription of oral chemo-
therapy. We estimated the relative influence of the route and tariff of administra-
tion, efficacy, tolerability and adherence on physician’s preferences. METHODS: A
Discrete Choice Experiment was performed among 203 French physicians qualified
in oncology. From an online questionnaire with six fictive scenarios, first presented
in curative setting then in palliative setting, respondents had to choose between
treatment A or B which differed with respect to efficacy, tolerability, adherence and
route of administration. Three of these attributes (efficacy, tolerability, adherence)
had two modalities (good vs. moderate) and the later (route of administration) had
three modalities: intravenous (€286–379/session in private and public hospital re-
spectively), oral with the current tariff (€28/consultation), oral with a fictive tariff
(€31/consultation and €83 for a patient support program). The relative influence of
attributes was analyzed using a conditional logistic regression model. RESULTS:
Efficacy was the predominant criteria in choosing a treatment either in curative
setting ( coefficient2.114, p0.0001) or in palliative setting (1.063, p0.0001).
Oral route of administration had a positive effect in palliative setting (0.612,
p0.035 for the current tariff and 0.506, p0.0001 for the fictive tariff). Removing
the efficacy attribute of the model, tolerability (1.228, p0.0001) and adherence
(1.223, p0.0001) were influent, but only in curative setting while the oral route
with a fictive tariff remained influential only in palliative setting (0.431,
p0.0001). CONCLUSIONS: The oral route of administration was influential in pal-
liative setting, which is consistent with the priority to preserve quality of life at the
advanced stage of disease. Physicians were sensitive to the fictive tariff for a pa-
tient support program, but as expected, in curative setting the key criterion re-
mains the efficacy.
PCN136
CANCER PATIENTS’ PERCEPTIONS TOWARDS THE INTEGRATION OF
TRADITIONAL & COMPLEMENTARY MEDICINES (T&CM) INTO THE
CONVENTIONAL CANCER TREATMENT: A QUALITATIVE INSIGHT
Farooqui M1, Hassali MA2, Knight AAS3, Akmal A4, Seang TB5, Farooqui MA6
1Universiti Teknologi MARA (UiTM), Sebrang Perai, Pulau Pinang, Malaysia, 2Universiti Sains
Malaysia, Minden, Pulau Pinang, Malaysia, 3Advanced Medical & Dental Institute, Kepala Batas,
Pulau Pinang, Malaysia, 4University Sains Malaysia, Penang, Penang, Malaysia, 5Penang
General Hospital, George Town, Pulau Pinang, Malaysia, 6Allianze University College of Medical
Sciences, Kepala Batas, Malaysia
OBJECTIVES: The national health care system encourages and supports the inte-
gration of T&CM into the conventional cancer treatment stream. The study aimed
to evaluate the perception of cancer patients towards the integration of T&CM into
their conventional therapies. METHODS: Qualitative methodology was adapted to
collect in-depth information from consented patients recruited from one of the
local hospitals with integrative medicines unit. After obtaining institutional ethical
approval, patients with different types of cancer and stages were approached.
Saturation point was reached after conducting 18 interviews as no new themes
emerged with subsequent interviews. All interviews were audiotaped, transcribed
verbatim and translated into English for thematic content analysis. RESULTS:
Mixed perceptions were shown towards the integration of traditional medicines
into the modern cancer treatment. All patients agreed with integrating traditional
therapies into their conventional health care plans only when the oncologists al-
low it. However, concerns were shown towards an implicit criticism of oncologists
regarding traditional medicines. Patients supported the use of traditional therapies
to overcome side effects due to conventional therapies provided the therapies are
proven for their safety with conventional medicines. For most of the patients,
cancer was perceived as a fatal disease and use of traditional therapies is among
the ways to put efforts for cure. Since the legitimacy of traditional medicines in the
country is among the challenges faced by the lawmakers, patients appreciated that
such efforts can prevent patients from being trapped by the quacks.
CONCLUSIONS: Patients showed signs of approval towards the integration or tra-
ditional medicines. However, patients would like their oncologists to provide and
supervise such therapies. At the same time, the challenge is to find a common
ground for an open discussion with modern health care practitioners towards
integration of traditional therapies into the modern cancer treatments.
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OBJECTIVES: Health state utilities are essential for health economic analysis. This
study assesses the utilities for different health states in breast cancer (BC ), com-
pares different HRQoL instruments and explores factors associated with poor
HRQoL. METHODS: An observational cross-sectional study among BC patients in
the Hospital District of Helsinki and Uusimaa was carried out between September
2009 and April 2011. A total of 778 BC patients (aged 31-90) assessed their HRQoL
with the generic 15D and EQ-5DVAS and the cancer specific EORTC-QLQ C30
HRQoL questionnaires. Patients were divided into five mutually exclusive groups
based on disease state: baseline before treatment (n52), 1st year of remission after
diagnosis or recurrence (n128), 2nd or following years after remission (n405),
metastatic disease (n177) and terminal care (n16). Linear stepwise regression
analysis was used to evaluate the association between the VAS-score and clinical
and demographic factors as well as the EORTC symptom and functioning scale
scores. RESULTS: The mean ( SD) utility values with 15D were for baseline pa-
tients 0.8960.083, 1st year of remission 0.9010.80, following years after remis-
sion 0.8840.103, metastatic disease 0.8250.113 and for palliative patients
0.7560.110 and with EQ-5D 0.8180.228, 0.8600.178, 0.8430.189, 0.7460.251,
0.5140.300, respectively. The difference between the instruments was consistent
in all states of the disease. In regression analysis, higher EORTC QLQ-C30 scores for
social, role and emotional functioning were associated with improved HRQoL.
However, the most important explanatory variable was higher education.
CONCLUSIONS: The utility scores were highest at 1st year of remission and dete-
riorated in the more advanced states of the disease. The 15D provided higher utility
values than the EQ-5D. The choice of the HRQoL instrument has a significant effect
on the utility values. Regression analysis showed that functioning has more impact
on HRQoL than symptoms or clinical and demographic parameters except for ed-
ucation.
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OBJECTIVES: The benefits of systemic treatment NSCLC patients are greater con-
trol of the symptoms and improvement of HRQoL. The study aimed to assess the
impact on daily living and HRQoL of the symptoms of advanced NSCLC.METHODS:
Observational study with prospective follow-up (basal and 6-8 week visit). 257
patients with stage IIIB NSCLC, with pleural/pericardial effusion or stage IV NSCLC,
about to initiate second-line treatment were included by 32 hospitals in Spain.
Demographic and clinical data relating to Lung Cancer Symptom Scale (LCSS) and
the lung-specific Functional Assessment of Cancer Therapy questionnaire
(FACT-L) were collected. Specific questions evaluating impact of symptoms on
patient daily life were included. RESULTS: By gender, 79.4% of patients were men,
the mean (SD) age was 63.7 (10.0) years. ECOG 1 was presented by 56.4% and 38.9%
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